Bionik Laboratories Corp.
BNKL
$0.0001
$0.000.00%
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 161.94% | 213.75% | 113.34% | -63.83% | -58.66% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 161.94% | 213.75% | 113.34% | -63.83% | -58.66% |
| Cost of Revenue | 321.50% | 504.17% | 133.13% | -42.38% | -54.00% |
| Gross Profit | 91.63% | 103.61% | 102.45% | -69.01% | -60.45% |
| SG&A Expenses | 10.60% | -5.59% | 7.20% | 0.09% | 14.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.64% | -5.41% | 25.83% | 9.70% | 11.41% |
| Operating Income | 11.15% | 31.71% | -6.68% | -71.26% | -44.94% |
| Income Before Tax | 20.46% | 84.59% | 10.93% | -206.96% | -64.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 20.46% | 84.59% | 10.93% | -206.96% | -64.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 20.46% | 84.59% | 10.93% | -206.96% | -64.77% |
| EBIT | 11.15% | 31.71% | -6.68% | -71.26% | -44.94% |
| EBITDA | 11.73% | 31.63% | -8.61% | -76.24% | -54.83% |
| EPS Basic | 33.26% | 86.78% | 24.16% | -154.36% | -44.49% |
| Normalized Basic EPS | 35.80% | 48.20% | 24.17% | -20.63% | -44.52% |
| EPS Diluted | 33.26% | 86.78% | 24.16% | -154.36% | -44.49% |
| Normalized Diluted EPS | 35.80% | 48.20% | 24.17% | -20.63% | -44.52% |
| Average Basic Shares Outstanding | 19.19% | 16.54% | 17.49% | 20.66% | 14.02% |
| Average Diluted Shares Outstanding | 19.19% | 16.54% | 17.49% | 20.66% | 14.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
